TRANSDERM SCOP Rx
Generic Name and Formulations:
Scopolamine 1.5mg (delivers approximately 1mg over 3 days); transdermal patch.
Novartis Consumer Health
Indications for TRANSDERM SCOP:
Prevention of motion sickness and post-op nausea and vomiting.
Apply to dry skin behind ear; do not cut patch. Motion sickness: 1 patch at least 4 hours before travel; remove after 72 hours. Post-op: 1 patch evening before surgery; for cesarean section: 1 patch 1 hour before surgery. Remove 24 hours after surgery.
Narrow angle glaucoma. Allergy to belladonna alkaloids.
Wash hands and skin after use; avoid eyes. GI or urinary tract obstruction. Hepatic, renal, or metabolic dysfunction. Seizure. Psychosis. Elderly. Pregnancy (Cat.C). Nursing mothers.
Alcohol, other CNS depressants potentiate CNS depression. Additive anticholinergic effects with other anticholinergics, antihistamines (e.g., meclizine), antidepressants. May affect absorption of other drugs.
Dry mouth, drowsiness, blurred vision, disorientation, confusion, difficult urination; withdrawal symptoms may occur if used for >3 days.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline